WR ClinSearch
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leathers, Vickie
NCT05207865: Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Completed
4
255
US
Rimegepant, BHV-3000
Pfizer
Migraine, Episodic Migraine, Phonophobia, Photophobia
07/24
07/24
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Peery, Marsha
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Riggs, Stephanie
Polaris-AD, NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease

Recruiting
3
1150
Europe, US, RoW
AR1001, Placebo
AriBio Co., Ltd.
Alzheimer Disease
12/25
12/27
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Botte, Jennifer
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Completed
2
63
US
TNX-102 SL, Placebo SL Tablet
Tonix Pharmaceuticals, Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
07/23
07/23
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Horner, Donald
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Glasco, Miasimone
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Peachy, Janet
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25

Download Options